209 related articles for article (PubMed ID: 12085207)
1. Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Choi JH; Lim HY; Joo HJ; Kim HS; Yi JW; Kim HC; Cho YK; Kim MW; Lee KB
Br J Cancer; 2002 May; 86(10):1578-85. PubMed ID: 12085207
[TBL] [Abstract][Full Text] [Related]
2. Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Choi J; Lim H; Nam DK; Kim HS; Cho DY; Yi JW; Kim HC; Cho YK; Kim MW; Joo HJ; Lee KB; Kim KB
Br J Cancer; 2001 Jan; 84(2):186-92. PubMed ID: 11161374
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG
Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454
[TBL] [Abstract][Full Text] [Related]
4. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
Chang HM; Jung KH; Kim TY; Kim WS; Yang HK; Lee KU; Choe KJ; Heo DS; Bang YJ; Kim NK
Ann Oncol; 2002 Nov; 13(11):1779-85. PubMed ID: 12419751
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
[TBL] [Abstract][Full Text] [Related]
6. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
[TBL] [Abstract][Full Text] [Related]
7. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
Kim SY; Park HC; Yoon C; Yoon HJ; Choi YM; Cho KS
Cancer; 1998 Nov; 83(10):2054-9. PubMed ID: 9827708
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Soong R; Shah N; Salto-Tellez M; Tai BC; Soo RA; Han HC; Ng SS; Tan WL; Zeps N; Joseph D; Diasio RB; Iacopetta B
Ann Oncol; 2008 May; 19(5):915-9. PubMed ID: 18245778
[TBL] [Abstract][Full Text] [Related]
9. 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion.
Choi JH; Kim YB; Lim HY; Park JS; Kim HC; Cho YK; Han SW; Kim MW; Joo HJ
Hepatogastroenterology; 2007; 54(73):290-7. PubMed ID: 17419278
[TBL] [Abstract][Full Text] [Related]
10. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy.
Lee J; Park CK; Park JO; Lim T; Park YS; Lim HY; Lee I; Sohn TS; Noh JH; Heo JS; Kim S; Lim DH; Kim KM; Kang WK
Clin Cancer Res; 2008 Jan; 14(1):82-8. PubMed ID: 18172256
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study.
Macdonald JS; Fleming TR; Peterson RF; Berenberg JL; McClure S; Chapman RA; Eyre HJ; Solanki D; Cruz AB; Gagliano R
Ann Surg Oncol; 1995 Nov; 2(6):488-94. PubMed ID: 8591078
[TBL] [Abstract][Full Text] [Related]
12. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.
Lise M; Nitti D; Marchet A; Sahmoud T; Buyse M; Duez N; Fiorentino M; Dos Santos JG; Labianca R; Rougier P
J Clin Oncol; 1995 Nov; 13(11):2757-63. PubMed ID: 7595735
[TBL] [Abstract][Full Text] [Related]
13. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer.
Popiela T; Kulig J; Czupryna A; Szczepanik AM; Zembala M
Gastric Cancer; 2004; 7(4):240-5. PubMed ID: 15616772
[TBL] [Abstract][Full Text] [Related]
14. Gastric carcinoma: curative resection and adjuvant chemotherapy.
Carrillo Hernández JF; Ernesto de Obaldía Castillo G; Ramírez Ortega C; Frías Mendivil M; Pardo M
Arch Med Res; 1994; 25(1):29-35. PubMed ID: 8019111
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for recurrence in stage II and III gastric cancer patients receiving a curative resection and postoperative adjuvant chemotherapy.
Tsujinaka T; Shiozaki H; Yano M; Kikkawa N; Takami M; Monden M
Oncol Rep; 2001; 8(1):33-8. PubMed ID: 11115565
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
Jeung HC; Moon YW; Rha SY; Yoo NC; Roh JK; Noh SH; Min JS; Kim BS; Chung HC
Ann Oncol; 2008 Mar; 19(3):520-6. PubMed ID: 18029971
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
Metzger R; Leichman CG; Danenberg KD; Danenberg PV; Lenz HJ; Hayashi K; Groshen S; Salonga D; Cohen H; Laine L; Crookes P; Silberman H; Baranda J; Konda B; Leichman L
J Clin Oncol; 1998 Jan; 16(1):309-16. PubMed ID: 9440758
[TBL] [Abstract][Full Text] [Related]
19. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.
Kim JS; Kim MA; Kim TM; Lee SH; Kim DW; Im SA; Kim TY; Kim WH; Yang HK; Heo DS; Bang YJ; Lee KU; Choe KJ; Kim NK
Br J Cancer; 2009 Mar; 100(5):732-8. PubMed ID: 19259093
[TBL] [Abstract][Full Text] [Related]
20. Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur.
Grau JJ; Domingo-Domenech J; Morente V; Pera M; Garcia-Valdecasas JC; Fuster J; Bombí A; Mellado B; Albanell J; Gascón P
Oncology; 2004; 66(3):226-33. PubMed ID: 15218314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
